Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do not under estimate musk...the sec harassment is a gnat on his priority issues of running his empire.... everytime..Musk sneezes....woke snowflakes scream they have covid...
Musk is providing sunlight to the twitter libs and they don't like being held to same stds as regular everyday people...sunlight is a great disinfectant...don't you agree.
How soon until the twitter snowflakes complain that they need another emotional stress day because Musk is hurting their heads.
Musk doesn't need to buy twitter....Twitter has already begun reprogramming algorithms that affected conservatives suppressed "follow" population account....how did some major conservative accounts jump 25% in 1 day.... coincidence/ one off / anomaly....sure keep dreaming ....
No peace until twitter cleans up its act...caveat emptor....cheers...ziggy
Research...investment firms...fidelity, td Waterhouse, robinhood, wells Fargo, etrade...etc...
Down load app and register.....then ach transfer funds from your bank to investing account...your now ready to trade.
Do not buy any stock at market price....always do a limit purchase as a newbie (imho)...do not chase a stock...you will lose.
Finally...cmgr is a highly volatile pink stock...I do not recommend starting your inventing experience here....do some DD... start with well recognized stock...apple, Google, amazon...etc....
Market is very volatile at present due to inflation index, the fed basis points increases, adjustments, and recession fears.
Find a stock you want...put a limit order in at 75% of market price....go have a beer and wait.
Good luck
Caveat emptor...cheers...ziggy
The bottom feeders lose their ability to post when markets forces adjust to reality...why???
Lol...ziggy
Please clarify your breakout assumption...hovering at subpenny does not instill confidence in a grounded investor...ziggy
I agree...we are heading for a recession...dow down over 1100points as of 12pm.
Fed will continue 50 basis point until inflation is cooled.
Housing market and credit cards usage will crumble due to fed fund rate incremental upward adjustments. Only way to cool our 30 trillion debt is through inflation...this was all planned by current government due to excessive free money distributed over the last 1.5 years....add another trillion if $10,000 college debt forgiveness goes through due to progressive dem party squeezing uncle Joe's coconuts.
"Come on man!!!!" As uncle Joe would say.
Btw...even in good time this stock will struggle until costs as contained, increased revenue stream is applied, stock dilution is curtailed, and bona-fide celebrities are added to this platform to gin up interest from Gen x, y, z.
Caveat emptor...cheers...ziggy
Volume still under 1million with finance news.....price change at +.002....needle did not move much....investors still on sidelines...need something significant to push this puppy back to .02 to .05.
Caveat emptor...cheers..ziggy
It ran hard and slipped on the dilution puddle...
Caveat emptor...cheers. ziggy
Can you clarify Sysx...money. thxs
Nice PR spin...how does this equate to revenue for cmgr....
As said in the movie ..Jerry Mcquire..
"Show me the money!!!"
Caveat emptor.. cheers..ziggy
Me too!
Wow...dvn 10 Q quarterly report...crushing it!!
Cheers...ziggy
A massive what?? Implosion or explosion??
My apologies...on 3/29/22...I predicted subpenny by summer....I guess we had summer weather today.
Caveat emptor
Cheers....ziggy
Pulled from yahoo finance...this stock could explode 4x if phase 3 does well...cheers ziggy
?
Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
April 25, 2022, 4:25 pm
PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and endoscopic endpoints for efficacy, in the twice daily 150 mg dose arm
Achieved clinical proof-of-concept and validation for oral, gut-restricted approach for ulcerative colitis via blockade of the alpha-4-beta-7-integrin pathway
Plans underway for a registrational Phase 3 study anchored around twice daily 150 mg dose of PN-943, pending regulatory guidance
Protagonist to host a conference call today at 6:00 p.m. ET
NEWARK, Calif., April 25, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) today announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).
"We are delighted with the strength of the results from the IDEAL study and look forward to working with the regulatory agencies as we prepare for a Phase 3 registrational program for PN-943 in moderate-to-severe ulcerative colitis," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist. "Our oral, gut-restricted alpha-4-beta-7-integrin antagonist agent PN-943 has demonstrated clinical efficacy on par with the approved injectable antibody drug working through the same biological target. We believe the results of the IDEAL study may be paradigm shifting and of broad scientific relevance in understanding IBD pathogenesis and gut-restricted drug development via intervention of the integrin-MAdCAM pathway. Based on its convenience of oral administration and the favorable efficacy and safety results observed to date, we believe that PN-943 has the potential to become a first-in-class, foundational oral medicine for individuals living with moderate-to-severe ulcerative colitis."
"With the IDEAL study, we have demonstrated clinical proof-of-concept and validation for potential treatment of ulcerative colitis via oral, gut-restricted blockade of the alpha-4-beta-7-integrin pathway," said Scott Plevy, M.D., Executive Vice President and Therapeutic Head of Gastroenterology at Protagonist. "The study assessed two doses of PN-943, 150 mg BID and 450 mg BID, and demonstrated a very clear and consistent treatment effect at the lower 150 mg BID dose across key endpoints. The dose response demonstrated by this study is consistent with several other modalities in the integrin pathway. The findings in the lower-dose arm provide consistent evidence of clinical efficacy and safety, and clear direction on the dosing regimen for the Phase 3 registrational program."
"The oral, gut-restricted agent PN-943 appears to exert similar effects at the twice daily 150 mg dose in comparison to the approved injectable alpha-4-beta-7-integrin antibody drug and its mechanism of action," said Bruce Sands, M.D., M.S., the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, principal investigator for the IDEAL study and consultant to Protagonist. "There is a clear unmet need and strong clinical benefit for patients with an oral agent working through such a proven IBD specific mechanism, and the IDEAL study results provide good rationale for moving PN-943 forward in a Phase 3 registrational study."
Summary of Key Results
IDEAL is a randomized, double-blinded, placebo-controlled, multicenter Phase 2 study to evaluate the safety and efficacy of PN-943, an oral, gut-restricted, alpha-4-beta-7-integrin antagonist. 159 patients with moderate-to-severe active UC were randomized to either twice daily (BID) with 450 mg or 150 mg PN-943, or placebo, for 12 weeks and analyzed for outcome measures.
While the 450 mg BID dose did not meet the prespecified primary endpoint, the 150 mg dose achieved a placebo versus treatment delta of 13% (p=0.08) in the modified Intent to Treat (mITT) group, and a delta of 16% (p=0.04) in the bio-naïve group. In addition, the 150 mg BID data showed strong concordance across multiple parameters including statistically significant histological remission and endoscopic improvement.
PN-943 150 mg BID dose forms the basis for a Phase 3 registrational program
27.5% clinical remission vs 14.5% in placebo (delta 13%, p=0.08) for mITT analysis
Strong concordance with efficacy across multiple key secondary endpoints with statistically significant differences in histologic remission/improvement and endoscopic improvement
Safety analysis similar for the 150 mg BID dose versus the placebo group
Just...pulled this...ziggy.
Protagonist Therapeutics: Biotechnology company Protagonist Therapeutics (NASDAQ:PTGX) remains on the Fintel short squeeze leaderboard at the same position it held last week. Fintel shows 12.8% of the float short and a borrow fee rate of 16.88. Short interest is climbing in the company’s shares, according to the report.
Trading volume picking up...let's see what happens.
Also....2.5 million shares traded is low for a 48 million market cap....
I smell shorts in the water right now!!!
Watch what happens in the next 4 hrs.....I truly think it was an aggressive short attack....a week ago...this was trading at $25....as of 10:30am today...$12.???????...a billion market cap company ...with $27 million rev and some analysts looking at $50 rating does not implode this quickly.....remember...they are going forward with 150mg dosage in their new drug via phase III.....but reevaluating the 450mg dosage that did not perform well..
..I think novice investors just panicked and dump when shorter attacked last night and they only read the negative test results... you have to have a set of stones to hold on right now....but a 4x return on my $12 price would be nice return for me.
Remember what Warren buffet say...".when investors are fearful...buy!!!"
Good luck...... cheers ziggy
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Protagonist Therapeutics (PTGX – Research Report), Gossamer Bio (GOSS – Research Report) and Black Diamond Therapeutics (BDTX – Research Report).
Protagonist Therapeutics (PTGX)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $50.00. The company’s shares closed last Monday at $18.80, close to its 52-week low of $12.80.
According to TipRanks.com, Tsao is a 3-star analyst with an average return of 3.2% and a 40.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines.
Protagonist Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $49.20, implying a 163.0% upside from current levels. In a report issued on April 11, BTIG also maintained a Buy rating on the stock with a $55.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Not sure....I thought buying back at 12 was a good bottom .... but see if you can bring some light to the avalanche! Ziggy
Cmgr is now below 52 week range at .016...
Subpenny by june.... imho. Ziggy
I like to see some feedback from draftking and Walmart on this promo deal.
Why would companies worth billions attached themselves to a small startup company like cmgr . .which main talent is stock dilution and pump pr statements.
Stock is taking a beating today.
Caveat emptor...ziggy
This has potential to rebound nicely after Thursdays dip of 25%.
Your logic here is like saying a "broken clock is always right right twice a day!"
I agree stock splits are extremely beneficial for stocks like apple, tesla and Amazon due to steady growth and revenue. Also the small investor has more opportunity to jump in at a lower price creating trade volume.
I also believe a reverse stock split a far more detrimental to shareholders as current shareholders get bleed to oblivion.
For now..the shorters of gme are scrambling as morning share price is up 15% due to stock split mania. In time you will get that entry point to short again. Good luck to all.
Caveats emptor......ziggy
Great intel....ziggy
If you can find updated Financials for 2022...we can take a closer look at cmgr and it's potential.
Ziggy
I'm a debating the cmgr financial relations department or a paid pumper? Please clarify.
If finance pr machine.... lets talk about cmgr Financials that they do report under pink sheets need to know guidelines.
1. Beside timely pr verbiage about what cmgr could achieve if all social media platforms fall into place....
How is cmgr generating current revenue besides share dilution?
How many employees does cmgr report...last I could find...1.....ie...major red flag!
How is cmgr containing cost to make on hand cash last?
Eloquent pr statements may stimulate newbies...but street savy investors on ihub don't bite on the hype.
IMHO....If you what to change investor mindset for cmgr.....show us some tangible financial results that have some teeth for financial growth and expansion.
Good luck ...caveat emptor...cheers..ziggy
I highly recommend you review some of my previous post from a year ago on stock price and financial statements.
1. Cmgr was $26 over a year ago due to Elon Musk tweeting support to a company with similar name...now cmgr trading at $.03.
2. 2020...operating loss per shareholders was $2.5 million...
3. 2021....Operating loss per shareholders was $5.7 million
4. O/S in 2020 was 88million shares.....now. O/S is 111million....22% increase in dilution
5. Only money/revenue generated is from share dilution ....to pay for pumpers to snag newbies!!!!
Caveat emptor....cheers....ziggy
As long as dumping shares are pumping this stock into dilution history...this stock is going nowhere..imho...subpenny by summer.
Caveat emptor...ziggy
$7 ceilings been broken...next leg $8 if Russia war continues!!!
Cheers..ziggy
I do...but I find options trading risky....quick gains...but easy to lose your shirt...cheers..ziggy
not sure if your still holding....myself..I would have sold at $1.3 for a quick 167% return on short-term investment....
where do you think io is heading? ziggy
Last day to purchase Altria 7% qtrly dividend date is March 23rd..ie to become stock holder of record....easy money...cheers..ziggy
"Altria Group, Inc. (NYSE:MO) Is About To Go Ex-Dividend, And It Pays A 7.0% Yield - Simply Wall St News" https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-mo/altria-group/news/altria-group-inc-nysemo-is-about-to-go-ex-dividend-and-it-pa/amp
Thanks for follow...no private messaging..ziggy
Great article from yahoo finance...must read from serious dvn potential investors..cheers..ziggy
Devon Energy (DVN) Down 2.6% Since Last Earnings Report: Can It Rebound?
"Devon Energy (DVN) Down 2.6% Since Last Earnings Report: Can It Rebound?" https://finance.yahoo.com/news/devon-energy-dvn-down-2-153003607.html
Workhorse Group CEO buys $155K in common stock
Source: Seeking Alpha
Shows confidence in wkhs future price and deliverables...ziggy
As predicted..recent dvn price decline was an orchestrated takedown after qtrly dividend declaration on 3.14.22.
Great fundamentals..pro analysts reviews...Russian oil losing clients every day...thus limiting overall global supply...Saudis not taking Biden's call (lol) and not increasing output
Back to $62+ and more by end of month.
Cheers... ziggy
Good choice..back to $62 ++ with progressive banning biden from drilling on fed land, LNG exports to Europe on stall via Biden, and more countries banning Russia oil and gas...prices at pump may hit $5 per gallon on average as world economies start to heat up post COVID-19.
Secondly China lock down of 51 million people in heavy mfg area for us consumer products is total bs.... just strategy to pressure usa to remove tariffs and create supply shortages in us....cheers..ziggy
All oil energy getting crushed thus week due to 51 million getting quarritined in China trying to control COVID-19 and China support for Russia.
Oil speculation push oil hard last week to $110....
I wonder how soon our local gas prices will adjust accordingly to drop in barrel price...yea right...lol....ziggy.